Genakumab

Primary objectives: – To evaluate the bioequivalence of the two formulations after a single subcutaneous injection. Secondary objectives: – To evaluate the safety of the test and reference formulations; – To evaluate the immunogenicity of the test and reference formulations.

Primary objective: To evaluate the safety and tolerability of multiple subcutaneous injections of kinumab for injection in patients with connective tissue disease-related interstitial lung disease. Secondary objective: To evaluate the pharmacokinetics (PK), immunogenicity, and efficacy of kinumab for injection after multiple subcutaneous injections in patients with connective tissue disease-related interstitial lung disease. Exploratory objective: To evaluate the pharmacodynamic (PD) characteristics, population pharmacokinetics (Pop PK), and dose-response analysis (E-R analysis) of kinumab for injection after multiple subcutaneous injections in patients with connective tissue disease-related interstitial lung disease.